Effect of Simultaneous Use of Platelet Glycoprotein IIb / IIIa Receptor Blocker and Thrombus Aspiration in Patients with Coronary Artery Stent Thrombosis
![]() |
Kim, In Soo
(Department of Radiology, Dongshin University)
Choi, Nam Gil (Department of Radiology, Dongshin University) Kong, Chang gi (Department of Radiology, Dongshin University) Eun, Sung jong (Department of Radiology, Hanlyo University) Han, Jae Bok (Department of Radiology, Dongshin University) |
1 | Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, "Analysis of 1-year clinical outcomes in the SIRIUS trial: randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis," Circulation, Vol. 109, No. 5, pp. 634-640, 2004. DOI |
2 | Salam AM, Al Suwaidi J, Holmes DR Jr, "Drug-eluting coronary stents," Curr Probl Cardiol, Vol. 31, No. 1, pp. 8-119, 2006. DOI |
3 | Stone GW, Maehara A, Witzenbichler B, "Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial," JAMA, Vol. 307, No. 17, pp. 1817-1826, 2012. DOI |
4 | De Luca G, Navarese EP, Suryapranata H, "A meta-analytic overview of thrombectomy during primary angioplasty," Int J Cardiol, Vol. 166, No. 3, pp. 606-612, 2013. DOI |
5 | S. Park, G. R. Hong, H. S. Seo, S. J. Tahk, "Stent thrombosis after successful drug-eluting stent implantation," Korean Circ J, Vol. 35, No. 2, pp. 163-71, 2005. DOI |
6 | Leon MB, Bakhai A, "Drug-eluting stents and glycoprotein IIb/III inhibitors: combination therapy for the future," Am Heart J, Vol. 146(4 Suppl), S13-7, 2003. DOI |
7 | Jeremias A, Sylvia B, Bridges J, "Stent thrombosis after successful sirolimus-eluting stent implantation," Circulation, Vol. 109, No. 16, pp. 1930-1932, 2004. DOI |
8 | D. W. Park, S. W. Park, "Stent thrombosis in the era of the drug-eluting stent," Korean Circ J, Vol. 35, No. 2, pp. 791-794, 2005. DOI |
9 | Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. "Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project," J Am Coll Cardiol, Vol. 47, No. 1, pp. 175-181, 2006. DOI |
10 | Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, "Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)," Lancet, Vol. 352, No. 9129, pp. 673-681, 1998. DOI |
11 | Burzotta F, Romagnoli E, Manzoli A, "The Outcome of PCI for stent-Thrombosis Multicentre Study (OPTIMIST) : rationale and design of a multicenter registry," Am Heart J, Vol. 153, No. 3, pp. 377. e1-5, 2007. DOI |
12 | Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Sings and Symptoms (PRISM-PLUS) Study Investigators, "Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction," N Engl J Med, Vol. 338, No. 21, pp. 1488-1497, 1998. DOI |
13 | Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS, "Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications," Am J Cardiol, Vol. 31, No. 1, pp. 31-36, 1998. |
14 | Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ, "Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade," Am J Cardiol, Vol. 82, No. 1, pp. 7-12, 1998. DOI |
15 | CAPTURE (C7E3 Fab AntiPlatelet Therapy in Unstable Refractory angina) Investigators, "Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina," Lancet, Vol. 349, No. 963, pp. 1429-1435, 1997. DOI |
16 | D. S. Sim, M. H. Jeong, J. C. Kang, "Clinical outcome in elderly patients older than 70years with acute myocardial infarction after use of platelet glycoprotein IIb/IIIa receptor blocker during percutaneous coronary intervention," Korean Journal of Internal Medicine, Vol. 67, No. 6, pp. 580-588, 2004. |
17 | Frobert O, Lagerqvist B, Gudnason T, "Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial): a multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish Angiography and Angioplasty Registry (SCAAR) platform: study design and rationale," Am Heart J, Vol. 160, No. 6, pp. 1042-1048, 2010. DOI |
18 | Lipiecki J, Monzy S, Durel N, "Effect of thrombus aspiration on infarct size and left ventricular function in highrisk patients with acute myocardial infarction treated by percutaneous coronary intervention: results of a prospective controlled pilot study," Am Heart J, Vol. 157, No. 3, pp. 583. e1-7, 2009. DOI |
19 | Haeck JD, Koch KT, Bilodeau L, "Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study," JACC Cardiovasc Interv, Vol. 2, No. 10, pp. 934-943, 2009. DOI |
20 | Svilaas T, Vlaar PJ, van der Horst IC, "Thrombus aspiration during primary percutaneous coronary intervention," N Engl J Med, Vol. 358, No. 6, pp. 557-567, 2008. DOI |
21 | Farb A, Boam AB, "Stent thrombosis redux: the FDA perspective," N Engl J Med, Vol. 356, No. 10, pp. 984-987, 2007. DOI |
22 | Daemen J, Wenaweser P, Tsuchida K, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study," Lancet, Vol. 369, No. 9562, pp. 667-678, 2007. DOI |
23 | I. S. Kim, M. H. Jeong, S. J. Jang, J. B. Han, and Y. I. Jang, "Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation," The Korea Contents Association, Vol. 13, No. 12, pp. 880-892, 2013. DOI |
24 | Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM, "Specific platelet mediators and unstable coronary artery lesions," Circulation, Vol. 80, No. 1, pp. 198-205, 1989. DOI |
25 | Steven P. Marso, A. Michael Lincoff, Stephen G. Ellis, Deepak L. Bhatt, Jean-Francois Tanguay, Neal S. Kleiman, Talal Hammoud, Joan E. Booth, Shelly K. Sapp, and Eric J. Topol, "Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy," Circulation, Vol. 100, No. 25, pp. 2477-2484, 1999. DOI |
26 | Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K, "Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor," Am Heart J, Vol. 130, No. 4, pp. 877-892, 1995. DOI |
27 | Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS, "Inhibition of platelet-medicaated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment an acute thrombosis and clinical restenosis," J Clin Invest, Vol. 98, No. 3, pp. 863-874, 1996. DOI |
28 | Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, "Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months," Lancet, Vol. 343, No. 8902, pp. 881-886, 1994. DOI |
29 | Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ, "Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions," Circulation, Vol. 102, No. 1, pp. 28-34, 2000. DOI |
30 | Coleman KR, Braden GA, Willingham MC, Sane DC, "Vitaxin, a humanized monoclonal antibody to the vitronectin receptor, reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits," Circ Res., Vol. 84, No. 11, pp. 1268-1276, 1999. DOI |
![]() |